Cancer immunotherapy trials: leading a paradigm shift in drug development.
about
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Combination immunotherapy: a road map.Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone.Patent trend and competitive analysis of cancer immunotherapy in the United States.Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
P2860
Cancer immunotherapy trials: leading a paradigm shift in drug development.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@en
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@nl
type
label
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@en
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@nl
prefLabel
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@en
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@nl
P2093
P2860
P1476
Cancer immunotherapy trials: leading a paradigm shift in drug development.
@en
P2093
F Stephen Hodi
Francesco M Marincola
Howard L Kaufman
Leisha A Emens
P2860
P2888
P356
10.1186/S40425-016-0146-9
P577
2016-07-19T00:00:00Z
P6179
1021995201